Ignite Creation Date:
2024-05-06 @ 5:43 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05408845
Status:
RECRUITING
Last Update Posted:
2024-02-07
First Post:
2022-06-02
Brief Title:
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment Chemotherapy With Docetaxel Plus Trastuzumab for Recurrent Metastatic or Unresectable HER2-Positive Salivary Gland Cancer
Sponsor:
Organization:
NRG Oncology
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
116
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: